SOUTH SAN FRANCISCO, Calif., July 26, 2018 /PRNewswire/ -- Sutro Biopharma, Inc., has secured $85.4 million in Series E financing to advance its wholly-owned pipeline of novel cancer therapeutics, including two internally-developed antibody drug conjugates, or ADCs, known as STRO-001, now ...